Henry Schein, Inc. (NASDAQ: HSIC) is a Healthcare company (Medical - Distribution) with a market capitalization of $9.2B. The Maz Rating grades it against the other companies in its sector.
Henry Schein, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $82.94, Henry Schein, Inc. trades at 22.6x trailing earnings, 0.7x sales and 2.9x book value, with an EV/EBITDA of 11.8. Over the last twelve months it generated about $13.6B of revenue and $405M of net income. It runs a gross margin of 30.6%, an operating margin of 5.7% and a net margin of 3.1%. It shows return on equity of 13.1%, return on invested capital of 6.5% and a free cash flow yield of 5.8%. On the balance sheet: a debt-to-equity ratio of 1.23 and a current ratio of 1.33. Over the past 52 weeks the share price ranged from $68.70 to $92.18, with a beta of 0.86.
Henry Schein, Inc. does not currently pay a dividend.
34 Wall Street analyst ratings cover the stock: 17 Buy, 14 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Henry Schein, Inc. (HSIC) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 36.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 1.88% / 30% · Interest income / Revenue 0.26% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 36.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 1.88% / 33% · Receivables / Mkt Cap (36m) 19.1% / 49% · Interest income / Revenue 0.26% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 36.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 1.88% / 33.33% · Receivables / Mkt Cap (24m) 19.1% / 33.33% · Interest income / Revenue 0.26% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 30.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 1.40% / 33.33% · Receivables / Avg Assets (4Q) 15.4% / 33.33% · Interest income / Revenue 0.26% / 5% | Pass |
| FTSE | Debt / Total Assets 31.3% / 33.33% · (Cash+ST Inv) / Total Assets 1.60% / 33.33% · (Cash+Recv) / Total Assets 17.9% / 33.33% · Interest income / Revenue 0.26% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Henry Schein, Inc. (HSIC) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. Henry Schein, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.26% of each dividend: Henry Schein, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 26, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.